Undifferentiated pleomorphic sarcoma

This study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) and radiation before surgery can help shrink tumors in people with two rare types of sarcoma. About 32 adults with these cancers that can be surgically removed will receive the treatment an…

This study tests whether adding three drugs (vincristine, irinotecan, and regorafenib) to standard chemotherapy can help people with Ewing sarcoma that has spread. About 437 participants will receive either the new combo or standard treatment. The goal is to see if the new approa…

This phase 2 trial tests whether combining NKTR-214 and nivolumab can shrink or control advanced sarcoma that has spread. About 88 people aged 12 and older with certain sarcoma types will receive both drugs every three weeks. The main goal is to see how many patients have their t…

This phase 2 trial tests whether injecting a modified herpes virus (TVEC) directly into tumors, combined with radiation therapy before surgery, can shrink advanced soft tissue sarcomas. The study enrolled 2 adults with specific sarcoma types that could not be removed with clear m…

This phase 2 study tests a combination of two drugs—talimogene laherparepvec (T-VEC), a virus that attacks cancer cells, and pembrolizumab, an immunotherapy that helps the immune system fight cancer—in 41 adults with advanced sarcoma that has spread or cannot be removed by surger…

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This study tests whether combining two drugs, lenvatinib and pembrolizumab, can safely shrink or control advanced soft tissue sarcomas that have spread or can't be removed by surgery. About 52 adults with specific sarcoma types will receive the combination. The goal is to measure…

This study tests whether adding the targeted drug cabozantinib to immunotherapy (ipilimumab and nivolumab) works better than immunotherapy alone for people with advanced soft tissue sarcoma that has spread. About 66 adults with specific sarcoma types will take part. The goal is t…

This early-phase study tests the safety of combining two immunotherapy drugs—nivolumab and BO-112—given before surgery for soft tissue sarcoma that can be removed. About 14 adults with certain sarcoma types will receive these drugs to see if they help the immune system fight the …

This pilot study is testing a radioactive antibody called 124I-Humanized 3F8 to see how it travels through the body and attaches to tumors in people with melanoma, neuroblastoma, or sarcoma. Seven participants will receive the antibody and then have PET/CT scans at several time p…

This study was designed for adults with certain types of soft tissue sarcoma that have specific immune cell clusters (TLS) in their tumors. Participants would have received pembrolizumab (immunotherapy) with or without olaparib (a DNA repair blocker) before surgery, followed by m…